Newer antidiabetic drugs and calorie restriction mimicry

Indian Journal of Endocrinology and Metabolism

Volumn 20, Issue 1, 2016, Pages 142-146

  Kalra, Sanjay ^a   Jacob, Jubbin ^b   Gupta, Yashdeep ^c  

^a India   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Alpha glucosidase inhibitors; canagliflozin; dapagliflozin; dipeptidyl peptidase 4 inhibitors; exenatide; exenatide QW; glucagon like peptide 1 receptor agonists inhibitors; liraglutide; metformin; pioglitazone; sodium glucose co transporter 2

Indexed keywords

EID: 84981243992     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.172242     Document Type: Article

References (20)

1. Anderson RM, Shanmuganayagam D, Weindruch R. Caloric restriction and aging: Studies in mice and monkeys. Toxicol Pathol 2009;37:47-51
2. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. J Nutr 1935;10:63-79
3. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012;489:318-21
4. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201-4
5. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
6. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA 2008;299:316-23
7. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14
8. Ingram DK, Zhu M, Mamczarz J, Zou S, Lane MA, Roth GS, et al. Calorie restriction mimetics: An emerging research field. Aging Cell 2006;5:97-108
9. Cantó C, Auwerx J. Calorie restriction: Is AMPK a key sensor and effector? Physiology (Bethesda) 2011;26:214-24
10. Scarpello JH. Improving survival with metformin: The evidence base today. Diabetes Metab 2003;29(4 Pt 2):6S36-43
11. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51
12. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: A therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 2014;7:241-53
13. Kalra S. Incretin enhancement without hyperinsulinemia: glucosidase inhibitors. Expert Rev Endocrinol Metab 2014;9:423-5
14. Ladenheim EE. Liraglutide and obesity: A review of the data so far. Drug Des Devel Ther 2015;9:1867-75
15. Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 2014;63:3346-58
16. Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 2013;39:71-9
17. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013;123:2764-72
18. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther 2014;5:355-66
19. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42
20. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 2015;169:631-8.e7.